Pipeline
Qu’s SSIs are uniquely positioned to treat and prevent cancer, chronic inflammatory diseases, and metabolic disease in a targeted organ.
Dr. Hal Gunn, CEO
SSI Pipeline: Advancing Clinical Programs Across Multiple Disease Areas
Therapeutic Area
SSI
Indication
Pre-clinical
Phase I
Phase II
Phase III
oncology
PERIOP-06 Study (RCT)
SSI
QBECO
Indication
Colon cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Lung Cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Pancreatic cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Ovarian Cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBSAU
Indication
Melanoma
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBSAU
Indication
Breast Cancer
Pre-clinical
Phase I
Phase II
Phase III
Pending clinical study in 2026
SSI
SSI/CAR T combo
Indication
Solid Tumors
Pre-clinical
Phase I
Phase II
Phase III
metabolic disease
SSI
QBECO
Indication
Fatty Liver Disease
Pre-clinical
Phase I
Phase II
Phase III
chronic inflammatory diseases
SSI
QBECO
Indication
Crohn's Disease (CD)
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Ulcerative Colitis (UC)
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Chronic Obstructive Pulmonary Disease
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Asthma
Pre-clinical
Phase I
Phase II
Phase III
Near Term Value Driving Milestones
- Qu Biologics has a randomized, double-blind, placebo-controlled clinical study underway (40% enrolled) in patients with late-stage colon cancer undergoing resection of liver metastases (n=115): PERIOP-06 Study. Milestone data anticipated Q2 2027.
- SSI/CAR T-cell combination study in solid tumors (n=15) pending, to initiate 2026, with data anticipated in Q2 2027